NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

Half year report part1

H1 2018 Group financial highlights

· Group reported revenues increased by 20.2% YoY to US$932.0m, with organic growth accounting for 13.4% of this growth
· EBITDA margin increased by 220bps to 24.2% as EBITDA growth (+32.1% to US$225.5m) continues to outpace revenue growth
· Financial and operational performance during H1 2018 remained in line with expectations, with management maintaining positive outlook for H2 2018

Half year report part2

Broker Forecast - JP Morgan Cazenove issues a broker note on NMC Health PLC
BFN
JP Morgan Cazenove today reaffirms its neutral investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4060p (from 3270p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

10:00 22/08/2018
Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
Barclays Capital today reaffirms its top pick investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4850p (from 4600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

21 Sep
Barclays...
N/A
Overweight
22 Aug
Barclays...
4,850.00
Top pick

i hold a few of these in my sipp, and thus with a fairly long term view
it's certainly a dangerous stock to try to trade as the chart shows, for it can be horribly volatile for no apparent reason

There was another UAE hospital/ health care provider I opened a thread for at the same time. I think they changed the company name, but this one has out performed it. Yes can be volatile.

Mediclinic International Plc (MDC) found it.

Not sure you will have heard of this company dream , but it has promise , it's called Versarien , AGM on Tues 25th , keep it to yourself as it could rocket soon .

Who are they? I hope you filled your boots on the normal pullback.

Suppose I should have learnt that by now , I'll have to get into this profit taking mentality , see it's on it's way back up now , it's the fear of news coming pre agm .

Playing with all profit only now, Which we all must have a very good balance. :-))

Going to be an interesting afternoon. Hold your hats on.lol

Capital Markets Day & Positively Revised Guidance
RNS
RNS Number : 6831E
NMC Health Plc
22 October 2018

22 October 2018

NMC Health plc
(the "Company" or "NMC")

Capital Markets Day and Positively Revised Guidance

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces that the Company will be holding a Capital Markets Day today at the London Stock Exchange.

Prashanth Shenoy, Chief Financial Officer of NMC Health, will provide an update on guidance given in January, following positive developments in the second half of 2018. As a result, we now anticipate an increase of 2% in revenue growth from 22% to 24% and an increased EBITDA guidance from $465m to $480m by year-end 2018.

2019 guidance will also point towards continuation of strong organic growth on the back of sustained ramp-up at key facilities, integration and expansion of acquired entities as well as strong operational performance. Revenues are forecast to increase by 22-24% and EBITDA is expected to increase by 18-20%. 2019 guidance does not include the effects of implementation of IFRS 16. The guidance also does not reflect the impact of anticipated financial consolidation of National Medical Care Company. An update in this regard will be provided once the joint-venture with Hassana/GOSI has been formalized, which is on track for completion during Q4 18.

During the year 2019, management also anticipates: 1) opening of new greenfield facilities, particularly in UAE, 2) continued ramp-up of various facilities across multiple geographies and 3) full-year consolidation of Aspen Healthcare, all of which will impact EBITDA margin.

Management remains confident on the longer-term margin guidance for the Company and NMC remains on track to achieve 25% EBITDA margin by 2020/2021.

10:00 23/10/2018
Broker Forecast - HSBC issues a broker note on NMC Health PLC
HSBC today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 1430p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Purchase of Shares
RNS
RNS Number : 8923F
NMC Health Plc
31 October 2018



NMC Health plc

Purchase of Shares


London, 31 October 2018: NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, received notification from Jonathan Bomford, the Senior Independent Director of the Company, that on 31 October 2018 he bought through his SIPP, 1,000 ordinary shares of 10p each in the Company ("Shares") at a price of 3475.545p pence per share.

Following this transaction, Jonathan Bomford's share interest, including the shares held by his spouse, has increased to 20,000 Shares, representing approximately 0.01% of the issued share capital of the Company.

a good healthcare company based in m/e, so not quite as susceptible to uk jitters
nevertheless, it can be quite volatile

have just topped up my sipp to an "average" holding

and a nice rise today of 6% perhaps on the back of an upgrade from jpm

Hopefully back above £40 :-))

09:50 27/11/2018
Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
Jefferies International today downgrades its investment rating on NMC Health PLC (LON:NMC) to underperform (from hold) and cut its price target to 2940p (from 3411p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk